{"protocolSection":{"identificationModule":{"nctId":"NCT03679767","orgStudyIdInfo":{"id":"INCMGA 0012-203"},"organization":{"fullName":"Incyte Corporation","class":"INDUSTRY"},"briefTitle":"A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)","officialTitle":"A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)"},"statusModule":{"statusVerifiedDate":"2023-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-01-09","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2021-04-15","type":"ACTUAL"},"completionDateStruct":{"date":"2022-06-28","type":"ACTUAL"},"studyFirstSubmitDate":"2018-09-19","studyFirstSubmitQcDate":"2018-09-19","studyFirstPostDateStruct":{"date":"2018-09-20","type":"ACTUAL"},"resultsFirstSubmitDate":"2022-04-13","resultsFirstSubmitQcDate":"2022-04-13","resultsFirstPostDateStruct":{"date":"2022-05-10","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-07-13","lastUpdatePostDateStruct":{"date":"2023-07-21","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Incyte Corporation","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been established."},"conditionsModule":{"conditions":["Metastatic Non-small Cell Lung Cancer","Locally Advanced Urothelial Cancer","Metastatic Urothelial Cancer","Unresectable Melanoma","Metastatic Melanoma","Locally Advanced Renal Cell Carcinoma","Metastatic Clear-Cell Renal Cell Carcinoma"],"keywords":["PD-1inhibitor","non-small cell lung cancer","urothelial cancer","melanoma","renal cell carcinoma"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":121,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Melanoma: retifanlimab 500 mg","type":"EXPERIMENTAL","description":"Participants with melanoma received retifanlimab 500 milligrams (mg) every 4 weeks (Q4W), administered by intravenous (IV) infusion over 30 minutes on Day 1 of each 28-day cycle.","interventionNames":["Drug: Retifanlimab"]},{"label":"NSCLC: retifanlimab 500 mg","type":"EXPERIMENTAL","description":"Participants with non-small cell lung cancer (NSCLC) received retifanlimab 500 mg Q4W, administered by IV infusion over 30 minutes on Day 1 of each 28-day cycle.","interventionNames":["Drug: Retifanlimab"]},{"label":"UC: retifanlimab 500 mg","type":"EXPERIMENTAL","description":"Participants with urethelial carcinoma (UC) received retifanlimab 500 mg Q4W, administered by IV infusion over 30 minutes on Day 1 of each 28-day cycle.","interventionNames":["Drug: Retifanlimab"]},{"label":"RCC: retifanlimab 500 mg","type":"EXPERIMENTAL","description":"Participants with renal cell carcinoma (RCC) received retifanlimab 500 mg Q4W, administered by IV infusion over 30 minutes on Day 1 of each 28-day cycle.","interventionNames":["Drug: Retifanlimab"]}],"interventions":[{"type":"DRUG","name":"Retifanlimab","description":"Retifanlimab administered intravenously at 500 mg every 4 weeks","armGroupLabels":["Melanoma: retifanlimab 500 mg","NSCLC: retifanlimab 500 mg","RCC: retifanlimab 500 mg","UC: retifanlimab 500 mg"],"otherNames":["INCMGA00012"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overall Response Rate (ORR)","description":"ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR), per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1), as determined by the investigator, at any post-Baseline visit until new anti-cancer therapy or first Progressive Disease. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \\<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.","timeFrame":"up to 25.9 months"}],"secondaryOutcomes":[{"measure":"Duration of Response (DOR)","description":"DOR was defined as the time from initial objective response (CR or PR) per RECIST v1.1 until the first observation of documented disease progression (PD), as determined by the investigator, or death due to any cause. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \\<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion.","timeFrame":"up to 24.0 months"},{"measure":"Disease Control Rate (DCR)","description":"DCR was defined as the proportion of participants with an overall response of CR, PR, or stable disease (SD), per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \\<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. SD: no change in target lesions to qualify for CR, PR, or PD.","timeFrame":"up to 25.9 months"},{"measure":"Progression-free Survival (PFS)","description":"According to RECIST 1.1, PFS was defined as the length of time from the initial infusion of study drug until the earliest date of disease progression, determined by investigator assessment, or death due to any cause, if occurring sooner than progression.","timeFrame":"up to 25.9 months"},{"measure":"Overall Survival","description":"Overall survival was defined as the time in months between the first dose date (Day 1) and the date of death due to any cause.","timeFrame":"up to 28.2 months"},{"measure":"Number of Participants With Treatment-emergent Adverse Events (TEAEs)","description":"An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of retifanlimab and until the earlier of 90 days of the last administration of retifanlimab and new anti-cancer therapy start if any, are reported.","timeFrame":"up to approximately 2.3 years"},{"measure":"First-dose Cmax of Retifanlimab","description":"Cmax was defined as the maximum observed plasma or serum concentration of retifanlimab.","timeFrame":"preinfusion and 10 minutes postinfusion (± 10 minutes) on Day 1 of Cycle 1"},{"measure":"Cmax of Retifanlimab at Steady-state","description":"Cmax was defined as the maximum observed plasma or serum concentration of retifanlimab.","timeFrame":"preinfusion and 10 minutes postinfusion (± 10 minutes) on Day 1 of Cycles 1, 2, 4, and 6 (up to approximately 168 days; each cycle was 28 days)"},{"measure":"First-dose Tmax of Retifanlimab","description":"tmax was defined as the time to the maximum concentration of retifanlimab.","timeFrame":"preinfusion and 10 minutes postinfusion (± 10 minutes) on Day 1 of Cycle 1"},{"measure":"Tmax of Retifanlimab at Steady-state","description":"tmax was defined as the time to the maximum concentration of retifanlimab.","timeFrame":"preinfusion and 10 minutes postinfusion (± 10 minutes) on Day 1 of Cycles 1, 2, 4, and 6 (up to approximately 168 days; each cycle was 28 days)"},{"measure":"First-dose Cmin of Retifanlimab","description":"Cmin was defined as the minimum observed plasma or serum concentration over the dose interval of retifanlimab.","timeFrame":"preinfusion and 10 minutes postinfusion (± 10 minutes) on Day 1 of Cycle 1"},{"measure":"Cmin of Retifanlimabv at Steady-state","description":"Cmin was defined as the minimum observed plasma or serum concentration over the dose interval of retifanlimab.","timeFrame":"preinfusion and 10 minutes postinfusion (± 10 minutes) on Day 1 of Cycles 1, 2, 4, and 6 (up to approximately 168 days; each cycle was 28 days)"},{"measure":"First-dose AUC0-t of Retifanlimab","description":"AUC0-t was defined as the area under the plasma or serum concentration-time curve from time = 0 to the last measurable concentration at time = t of retifanlimab.","timeFrame":"preinfusion and 10 minutes postinfusion (± 10 minutes) on Day 1 of Cycle 1"},{"measure":"AUC0-t of Retifanlimab at Steady-state","description":"AUC0-t was defined as the area under the plasma or serum concentration-time curve from time = 0 to the last measurable concentration at time = t of retifanlimab.","timeFrame":"preinfusion and 10 minutes postinfusion (± 10 minutes) on Day 1 of Cycles 1, 2, 4, and 6 (up to approximately 168 days; each cycle was 28 days)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Confirmed diagnosis of one of the following: treatment-naïve metastatic non-small cell lung cancer with high PD-L1 expression (tumor proportion score ≥ 50%) and no epidermal growth factor receptor (EGFR), alkaline phosphatase (ALK), or ROS activating genomic tumor aberrations; locally advanced or metastatic urothelial carcinoma in participants who are not eligible for cisplatin therapy and whose tumors express PD-L1 with a combined positive score ≥ 10; unresectable or metastatic melanoma; locally advanced or metastatic renal cell carcinoma with clear cell component (with or without sarcomatoid features) and having received no prior systemic therapy.\n* Measurable disease per RECIST v1.1.\n* Eastern Cooperative Oncology Group performance status 0 to 1.\n* Willingness to avoid pregnancy or fathering children.\n\nExclusion Criteria:\n\n* Receipt of anticancer therapy or participation in another interventional clinical study within 21 days before the first administration of study drug.\n* Prior treatment with PD-1 or PD-L1 directed therapy (other immunotherapies may be acceptable with prior approval from the medical monitor).\n* Radiotherapy within 14 days of first dose of study treatment with the following caveats: 28 days for pelvic radiotherapy; 6 months for thoracic region radiotherapy that is \\> 30 Gy.\n* Toxicity of prior therapy that has not recovered to ≤ Grade 1 or baseline (with the exception of anemia not requiring transfusion support and any grade of alopecia). Endocrinopathy, if well-managed, is not exclusionary and should be discussed with sponsor medical monitor.\n* Has not recovered adequately from toxicities and/or complications from surgical intervention before starting study drug.\n* Laboratory values outside the protocol-defined range at screening.\n* Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 3 years of study entry.\n* Active autoimmune disease requiring systemic immunosuppression in excess of physiologic maintenance doses of corticosteroids (\\> 10 mg of prednisone or equivalent).\n* Evidence of interstitial lung disease or active noninfectious pneumonitis.\n* Known active central nervous system metastases and/or carcinomatous meningitis.\n* Known active hepatitis B antigen, hepatitis B virus, or hepatitis C virus infection.\n* Active infections requiring systemic therapy.\n* Known to be HIV-positive, unless all of the following criteria are met: CD4+ count ≥ 300/μL, undetectable viral load, receiving antiretroviral therapy.\n* Known hypersensitivity to another monoclonal antibody that cannot be controlled with standard measures (eg, antihistamines and corticosteroids).\n* Impaired cardiac function or clinically significant cardiac disease.\n* Is pregnant or breastfeeding.\n* Has received a live vaccine within 28 days of the planned start of study drug.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Mark Cornfeld, MD","affiliation":"Incyte Corporation","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"California Cancer Associates for Research and Excellence, Inc.","city":"Fresno","state":"California","zip":"93720","country":"United States","geoPoint":{"lat":36.74773,"lon":-119.77237}},{"facility":"California Cancer Associates for Research and Excellence","city":"Fresno","state":"California","zip":"93720","country":"United States","geoPoint":{"lat":36.74773,"lon":-119.77237}},{"facility":"California Cancer Associates for Research and Excellence, Inc.","city":"San Marcos","state":"California","zip":"92069","country":"United States","geoPoint":{"lat":33.14337,"lon":-117.16614}},{"facility":"St Joseph Heritage Healthcare","city":"Santa Rosa","state":"California","zip":"95403","country":"United States","geoPoint":{"lat":38.44047,"lon":-122.71443}},{"facility":"St. Joseph Health Medical Group - Annadel Medical Group","city":"Santa Rosa","state":"California","zip":"95403","country":"United States","geoPoint":{"lat":38.44047,"lon":-122.71443}},{"facility":"Rocky Mountain Cancer Centers - Denver - Midtown","city":"Denver","state":"Colorado","zip":"80218","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"Christiana Care Helen F. Graham Cancer Center","city":"Newark","state":"Delaware","zip":"19718","country":"United States","geoPoint":{"lat":39.68372,"lon":-75.74966}},{"facility":"Rcca Md, Llc","city":"Bethesda","state":"Maryland","zip":"20817","country":"United States","geoPoint":{"lat":38.98067,"lon":-77.10026}},{"facility":"VA New Jersey Health Care System","city":"East Orange","state":"New Jersey","zip":"07018","country":"United States","geoPoint":{"lat":40.76732,"lon":-74.20487}},{"facility":"New York Oncology Hematology - Albany","city":"Albany","state":"New York","zip":"12208","country":"United States","geoPoint":{"lat":42.65258,"lon":-73.75623}},{"facility":"Kaiser Permanente","city":"Portland","state":"Oregon","zip":"97227","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Texas Oncology Surgical Specialists - Austin Central","city":"Austin","state":"Texas","zip":"78731","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Coastal Bend Cancer Center","city":"Corpus Christi","state":"Texas","zip":"78404","country":"United States","geoPoint":{"lat":27.80058,"lon":-97.39638}},{"facility":"AIM Trials, LLC","city":"Plano","state":"Texas","zip":"75093","country":"United States","geoPoint":{"lat":33.01984,"lon":-96.69889}},{"facility":"Texas Oncology - San Antonio Northeast","city":"San Antonio","state":"Texas","zip":"78217","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Oncology and Hematology Associates of Southwest Virginia, Inc.","city":"The Woodlands","state":"Texas","zip":"77380","country":"United States","geoPoint":{"lat":30.15799,"lon":-95.48938}},{"facility":"Texas Oncology - Waco","city":"Waco","state":"Texas","zip":"76712","country":"United States","geoPoint":{"lat":31.54933,"lon":-97.14667}},{"facility":"Oncology & Hematology Associates of Southwest Virginia, Inc.","city":"Wytheville","state":"Virginia","zip":"24382","country":"United States","geoPoint":{"lat":36.94845,"lon":-81.08481}},{"facility":"LKH Graz","city":"Graz","country":"Austria","geoPoint":{"lat":47.06733,"lon":15.44197}},{"facility":"Medizinische Universitat Innsbruck","city":"Innsbruck","zip":"A-6020","country":"Austria","geoPoint":{"lat":47.26266,"lon":11.39454}},{"facility":"Ordensklinikum","city":"Linz","zip":"4010","country":"Austria","geoPoint":{"lat":48.30639,"lon":14.28611}},{"facility":"Universitatsklinikum St. Polten","city":"Sankt Pölten","zip":"3100","country":"Austria","geoPoint":{"lat":48.20762,"lon":15.63725}},{"facility":"Institut Bergonié","city":"Bordeaux","zip":"33076","country":"France","geoPoint":{"lat":44.84124,"lon":-0.58046}},{"facility":"Institut Paoli Calmettes","city":"Marseille","zip":"13009","country":"France","geoPoint":{"lat":43.29695,"lon":5.38107}},{"facility":"CEPCM / CHU Timone","city":"Marseille","zip":"13885","country":"France","geoPoint":{"lat":43.29695,"lon":5.38107}},{"facility":"Georges Pompidou European Hospital","city":"Paris","zip":"75015","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Hopitaux Universitaires De Strasbourg","city":"Strasbourg","zip":"67091","country":"France","geoPoint":{"lat":48.58392,"lon":7.74553}},{"facility":"BAZ County Hospital","city":"Miskolc","zip":"3526","country":"Hungary","geoPoint":{"lat":48.10327,"lon":20.77806}},{"facility":"Hetenyi G Korhaz, Onkologiai Kozpont","city":"Szolnok","zip":"5004","country":"Hungary","geoPoint":{"lat":47.18066,"lon":20.19835}},{"facility":"Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona","city":"Ancona","zip":"60126","country":"Italy","geoPoint":{"lat":43.60717,"lon":13.5103}},{"facility":"ASST Istituti Ospitalieri","city":"Cremona","zip":"26100","country":"Italy","geoPoint":{"lat":45.13325,"lon":10.02129}},{"facility":"Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori","city":"Meldola","zip":"47014","country":"Italy","geoPoint":{"lat":44.12775,"lon":12.0626}},{"facility":"Istituto Nazionale Tumori Regina Elena","city":"Rome","zip":"00144","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"Azienda Ospedaliera Universitaria Senese","city":"Siena","zip":"53100","country":"Italy","geoPoint":{"lat":43.31822,"lon":11.33064}},{"facility":"Med-Polonia Sp. z o. o.","city":"Poznan","state":"Greater Poland Voivodeship","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"Centrum Onkologii- Instytut im Marii Skłodowskiej Curie","city":"Warsaw","state":"Masovian Voivodeship","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Specjalistyczna Praktyka Lekarska","city":"Lublin","zip":"20-093","country":"Poland","geoPoint":{"lat":51.25058,"lon":22.57009}},{"facility":"BioVirtus Research Site","city":"Otwock","zip":"05-400","country":"Poland","geoPoint":{"lat":52.10577,"lon":21.26129}},{"facility":"Centrul de Oncologie Sfantul Nectarie","city":"Craiova","state":"Dolj","zip":"200347","country":"Romania","geoPoint":{"lat":44.31667,"lon":23.8}},{"facility":"Oncolab SRL","city":"Craiova","state":"Dolj","zip":"200385","country":"Romania","geoPoint":{"lat":44.31667,"lon":23.8}},{"facility":"Medisprof SRL","city":"Cluj-Napoca","zip":"400461","country":"Romania","geoPoint":{"lat":46.76667,"lon":23.6}},{"facility":"Clinical Emergency Hospital of Constanta","city":"Constanța","zip":"900591","country":"Romania","geoPoint":{"lat":44.18073,"lon":28.63432}},{"facility":"Center of Oncology Euroclinic","city":"Iași","zip":"700106","country":"Romania","geoPoint":{"lat":47.16667,"lon":27.6}},{"facility":"Spitalul Clinic Judetean de Urgenta Sibiu","city":"Sibiu","zip":"550245","country":"Romania","geoPoint":{"lat":45.8,"lon":24.15}},{"facility":"Oncocenter - Oncologie Clinica SRL","city":"Timișoara","zip":"300166","country":"Romania","geoPoint":{"lat":45.75372,"lon":21.22571}},{"facility":"Hospital Universitari Parc Tauli","city":"Sabadell","state":"Barcelona","zip":"08208","country":"Spain","geoPoint":{"lat":41.54329,"lon":2.10942}},{"facility":"Centro Oncologico De Galicia","city":"A Coruña","zip":"08041","country":"Spain","geoPoint":{"lat":43.37135,"lon":-8.396}},{"facility":"Hospital de la Santa Creu i Sant Pau","city":"Barcelona","zip":"08025","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitario Vall d'Hebron","city":"Barcelona","zip":"08025","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"MD Anderson Cancer Center Madrid","city":"Madrid","zip":"28033","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Puerta De Hierro","city":"Majadahonda","zip":"28220","country":"Spain","geoPoint":{"lat":40.47353,"lon":-3.87182}},{"facility":"Hospital Universitari La Fe","city":"Valencia","zip":"46026","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 121 participants with advanced solid tumors (melanoma, non-small cell lung cancer, urethelial carcinoma, and renal cell carcinoma) were enrolled in the study and treated with retifanlimab.","recruitmentDetails":"This study was conducted at 34 study centers in Austria, Spain, France, Hungary, Italy, Poland, Romania, and the United States.","groups":[{"id":"FG000","title":"Melanoma","description":"Participants with melanoma received retifanlimab 500 milligrams (mg), administered by intravenous (IV) infusion over 30 minutes on Day 1 of each 28-day cycle (Q4W)."},{"id":"FG001","title":"Non-small Cell Lung Cancer","description":"Participants with non-small cell lung cancer received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."},{"id":"FG002","title":"Urethelial Carcinoma","description":"Participants with urethelial carcinoma received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."},{"id":"FG003","title":"Renal Cell Carcinoma","description":"Participants with renal cell carcinoma received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"35"},{"groupId":"FG001","numSubjects":"23"},{"groupId":"FG002","numSubjects":"29"},{"groupId":"FG003","numSubjects":"34"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"35"},{"groupId":"FG001","numSubjects":"23"},{"groupId":"FG002","numSubjects":"29"},{"groupId":"FG003","numSubjects":"34"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"11"},{"groupId":"FG002","numSubjects":"17"},{"groupId":"FG003","numSubjects":"10"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Follow-up Completed","reasons":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"11"},{"groupId":"FG002","numSubjects":"11"},{"groupId":"FG003","numSubjects":"20"}]},{"type":"Entered Hospice Care","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Progressive Disease","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Melanoma","description":"Participants with melanoma received retifanlimab 500 milligrams (mg), administered by intravenous (IV) infusion over 30 minutes on Day 1 of each 28-day cycle (Q4W)."},{"id":"BG001","title":"Non-small Cell Lung Cancer","description":"Participants with non-small cell lung cancer received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."},{"id":"BG002","title":"Urethelial Carcinoma","description":"Participants with urethelial carcinoma received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."},{"id":"BG003","title":"Renal Cell Carcinoma","description":"Participants with renal cell carcinoma received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"29"},{"groupId":"BG003","value":"34"},{"groupId":"BG004","value":"121"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"67.2","spread":"15.24"},{"groupId":"BG001","value":"67.8","spread":"8.68"},{"groupId":"BG002","value":"72.0","spread":"8.23"},{"groupId":"BG003","value":"66.6","spread":"10.28"},{"groupId":"BG004","value":"68.3","spread":"11.36"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"41"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"25"},{"groupId":"BG003","value":"24"},{"groupId":"BG004","value":"80"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"White/Caucasian","categories":[{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"33"},{"groupId":"BG004","value":"110"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}]}]},{"title":"Not Reported","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"10"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Hispanic or Latino","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"5"}]}]},{"title":"Not Hispanic or Latino","categories":[{"measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"29"},{"groupId":"BG004","value":"93"}]}]},{"title":"Not Reported","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"23"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Response Rate (ORR)","description":"ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR), per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1), as determined by the investigator, at any post-Baseline visit until new anti-cancer therapy or first Progressive Disease. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \\<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.","populationDescription":"Full Analysis Set (FAS) Population: all study participants who had received at least 1 dose of study drug. Participants were to be analyzed based on disease-specific diagnosis. Confidence intervals were calculated based on the exact method for binomial distributions.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"up to 25.9 months","groups":[{"id":"OG000","title":"Melanoma","description":"Participants with melanoma received retifanlimab 500 milligrams (mg), administered by intravenous (IV) infusion over 30 minutes on Day 1 of each 28-day cycle (Q4W)."},{"id":"OG001","title":"Non-small Cell Lung Cancer","description":"Participants with non-small cell lung cancer received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."},{"id":"OG002","title":"Urethelial Carcinoma","description":"Participants with urethelial carcinoma received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."},{"id":"OG003","title":"Renal Cell Carcinoma","description":"Participants with renal cell carcinoma received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"34"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.0","lowerLimit":"23.9","upperLimit":"57.9"},{"groupId":"OG001","value":"34.8","lowerLimit":"16.4","upperLimit":"57.3"},{"groupId":"OG002","value":"37.9","lowerLimit":"20.7","upperLimit":"57.7"},{"groupId":"OG003","value":"23.5","lowerLimit":"10.7","upperLimit":"41.2"}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DOR)","description":"DOR was defined as the time from initial objective response (CR or PR) per RECIST v1.1 until the first observation of documented disease progression (PD), as determined by the investigator, or death due to any cause. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \\<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion.","populationDescription":"FAS Population. Only those participants with a CR or PR were included in the analysis. The 95% confidence interval was calculated using the Brookmeyer and Crowley's method and Klein and Moeschberger's method with log-log transformation.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"up to 24.0 months","groups":[{"id":"OG000","title":"Melanoma","description":"Participants with melanoma received retifanlimab 500 milligrams (mg), administered by intravenous (IV) infusion over 30 minutes on Day 1 of each 28-day cycle (Q4W)."},{"id":"OG001","title":"Non-small Cell Lung Cancer","description":"Participants with non-small cell lung cancer received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."},{"id":"OG002","title":"Urethelial Carcinoma","description":"Participants with urethelial carcinoma received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."},{"id":"OG003","title":"Renal Cell Carcinoma","description":"Participants with renal cell carcinoma received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"9.2","upperLimit":"NA","comment":"The median and upper limit of the confidence interval were not estimable because too few participants had events of disease progression or death."},{"groupId":"OG001","value":"18.2","lowerLimit":"1.9","upperLimit":"NA","comment":"The upper limit of the confidence interval was not estimable because too few participants had events of disease progression or death."},{"groupId":"OG002","value":"11.5","lowerLimit":"2.2","upperLimit":"NA","comment":"The upper limit of the confidence interval was not estimable because too few participants had events of disease progression or death."},{"groupId":"OG003","value":"NA","lowerLimit":"2.8","upperLimit":"NA","comment":"The median and upper limit of the confidence interval were not estimable because too few participants had events of disease progression or death"}]}]}]},{"type":"SECONDARY","title":"Disease Control Rate (DCR)","description":"DCR was defined as the proportion of participants with an overall response of CR, PR, or stable disease (SD), per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \\<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. SD: no change in target lesions to qualify for CR, PR, or PD.","populationDescription":"FAS Population. Confidence intervals were calculated based on the exact method for binomial distributions.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"up to 25.9 months","groups":[{"id":"OG000","title":"Melanoma","description":"Participants with melanoma received retifanlimab 500 milligrams (mg), administered by intravenous (IV) infusion over 30 minutes on Day 1 of each 28-day cycle (Q4W)."},{"id":"OG001","title":"Non-small Cell Lung Cancer","description":"Participants with non-small cell lung cancer received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."},{"id":"OG002","title":"Urethelial Carcinoma","description":"Participants with urethelial carcinoma received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."},{"id":"OG003","title":"Renal Cell Carcinoma","description":"Participants with renal cell carcinoma received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"34"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.3","lowerLimit":"36.6","upperLimit":"71.2"},{"groupId":"OG001","value":"65.2","lowerLimit":"42.7","upperLimit":"83.6"},{"groupId":"OG002","value":"55.2","lowerLimit":"35.7","upperLimit":"73.6"},{"groupId":"OG003","value":"64.7","lowerLimit":"46.5","upperLimit":"80.3"}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS)","description":"According to RECIST 1.1, PFS was defined as the length of time from the initial infusion of study drug until the earliest date of disease progression, determined by investigator assessment, or death due to any cause, if occurring sooner than progression.","populationDescription":"FAS Population. Median PFS was estimated using the Kaplan-Meier method. The confidence interval for median PFS was calculated using the method of Brookmeyer and Crowley.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"up to 25.9 months","groups":[{"id":"OG000","title":"Melanoma","description":"Participants with melanoma received retifanlimab 500 milligrams (mg), administered by intravenous (IV) infusion over 30 minutes on Day 1 of each 28-day cycle (Q4W)."},{"id":"OG001","title":"Non-small Cell Lung Cancer","description":"Participants with non-small cell lung cancer received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."},{"id":"OG002","title":"Urethelial Carcinoma","description":"Participants with urethelial carcinoma received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."},{"id":"OG003","title":"Renal Cell Carcinoma","description":"Participants with renal cell carcinoma received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"34"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","lowerLimit":"1.8","upperLimit":"NA","comment":"The upper limit of the confidence interval was not estimable because too few participants had events of disease progression or death."},{"groupId":"OG001","value":"4.4","lowerLimit":"1.8","upperLimit":"21.9"},{"groupId":"OG002","value":"5.7","lowerLimit":"1.8","upperLimit":"13.6"},{"groupId":"OG003","value":"5.4","lowerLimit":"2.3","upperLimit":"11.4"}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival was defined as the time in months between the first dose date (Day 1) and the date of death due to any cause.","populationDescription":"FAS Population. Median survival time in months was estimated using the Kaplan-Meier method. The confidence interval for median survival time was calculated using the method of Brookmeyer and Crowley.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"up to 28.2 months","groups":[{"id":"OG000","title":"Melanoma","description":"Participants with melanoma received retifanlimab 500 milligrams (mg), administered by intravenous (IV) infusion over 30 minutes on Day 1 of each 28-day cycle (Q4W)."},{"id":"OG001","title":"Non-small Cell Lung Cancer","description":"Participants with non-small cell lung cancer received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."},{"id":"OG002","title":"Urethelial Carcinoma","description":"Participants with urethelial carcinoma received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."},{"id":"OG003","title":"Renal Cell Carcinoma","description":"Participants with renal cell carcinoma received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"34"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"8.7","upperLimit":"NA","comment":"The median and the upper limit of the confidence interval were not estimable because too few participants had events of death."},{"groupId":"OG001","value":"21.9","lowerLimit":"5.2","upperLimit":"NA","comment":"The upper limit of the confidence interval was not estimable because too few participants had events of death."},{"groupId":"OG002","value":"15.2","lowerLimit":"7.7","upperLimit":"NA","comment":"The upper limit of the confidence interval was not estimable because too few participants had events of death."},{"groupId":"OG003","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"The median and the upper and lower limits of the confidence interval were not estimable because too few participants had events of death."}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-emergent Adverse Events (TEAEs)","description":"An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of retifanlimab and until the earlier of 90 days of the last administration of retifanlimab and new anti-cancer therapy start if any, are reported.","populationDescription":"Safety Evaluable Population: all participants who received at least 1 dose of study drug","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"up to approximately 2.3 years","groups":[{"id":"OG000","title":"Melanoma","description":"Participants with melanoma received retifanlimab 500 milligrams (mg), administered by intravenous (IV) infusion over 30 minutes on Day 1 of each 28-day cycle (Q4W)."},{"id":"OG001","title":"Non-small Cell Lung Cancer","description":"Participants with non-small cell lung cancer received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."},{"id":"OG002","title":"Urethelial Carcinoma","description":"Participants with urethelial carcinoma received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."},{"id":"OG003","title":"Renal Cell Carcinoma","description":"Participants with renal cell carcinoma received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"34"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"32"}]}]}]},{"type":"SECONDARY","title":"First-dose Cmax of Retifanlimab","description":"Cmax was defined as the maximum observed plasma or serum concentration of retifanlimab.","populationDescription":"Pharmacokinetic (PK) Evaluable Population: all participants who received at least 1 dose of study drug and provided a Baseline and at least 1 postdose PK sample","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"milligrams per Liter (mg/L)","timeFrame":"preinfusion and 10 minutes postinfusion (± 10 minutes) on Day 1 of Cycle 1","groups":[{"id":"OG000","title":"All Participants","description":"Participants with melanoma, non-small cell lung cancer, urethelial carcinoma, and renal cell carcinoma received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"121"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"143","spread":"30.9"}]}]}]},{"type":"SECONDARY","title":"Cmax of Retifanlimab at Steady-state","description":"Cmax was defined as the maximum observed plasma or serum concentration of retifanlimab.","populationDescription":"PK Evaluable Population","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mg/L","timeFrame":"preinfusion and 10 minutes postinfusion (± 10 minutes) on Day 1 of Cycles 1, 2, 4, and 6 (up to approximately 168 days; each cycle was 28 days)","groups":[{"id":"OG000","title":"All Participants","description":"Participants with melanoma, non-small cell lung cancer, urethelial carcinoma, and renal cell carcinoma received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"121"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"181","spread":"39.4"}]}]}]},{"type":"SECONDARY","title":"First-dose Tmax of Retifanlimab","description":"tmax was defined as the time to the maximum concentration of retifanlimab.","populationDescription":"PK Evaluable Population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"hours","timeFrame":"preinfusion and 10 minutes postinfusion (± 10 minutes) on Day 1 of Cycle 1","groups":[{"id":"OG000","title":"All Participants","description":"Participants with melanoma, non-small cell lung cancer, urethelial carcinoma, and renal cell carcinoma received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"121"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.500","lowerLimit":"0.500","upperLimit":"1.00"}]}]}]},{"type":"SECONDARY","title":"Tmax of Retifanlimab at Steady-state","description":"tmax was defined as the time to the maximum concentration of retifanlimab.","populationDescription":"PK Evaluable Population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"hours","timeFrame":"preinfusion and 10 minutes postinfusion (± 10 minutes) on Day 1 of Cycles 1, 2, 4, and 6 (up to approximately 168 days; each cycle was 28 days)","groups":[{"id":"OG000","title":"All Participants","description":"Participants with melanoma, non-small cell lung cancer, urethelial carcinoma, and renal cell carcinoma received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"121"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.500","lowerLimit":"0.500","upperLimit":"1.00"}]}]}]},{"type":"SECONDARY","title":"First-dose Cmin of Retifanlimab","description":"Cmin was defined as the minimum observed plasma or serum concentration over the dose interval of retifanlimab.","populationDescription":"PK Evaluable Population","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mg/L","timeFrame":"preinfusion and 10 minutes postinfusion (± 10 minutes) on Day 1 of Cycle 1","groups":[{"id":"OG000","title":"All Participants","description":"Participants with melanoma, non-small cell lung cancer, urethelial carcinoma, and renal cell carcinoma received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"121"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","spread":"7.52"}]}]}]},{"type":"SECONDARY","title":"Cmin of Retifanlimabv at Steady-state","description":"Cmin was defined as the minimum observed plasma or serum concentration over the dose interval of retifanlimab.","populationDescription":"PK Evaluable Population","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mg/L","timeFrame":"preinfusion and 10 minutes postinfusion (± 10 minutes) on Day 1 of Cycles 1, 2, 4, and 6 (up to approximately 168 days; each cycle was 28 days)","groups":[{"id":"OG000","title":"All Participants","description":"Participants with melanoma, non-small cell lung cancer, urethelial carcinoma, and renal cell carcinoma received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"121"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.2","spread":"16.3"}]}]}]},{"type":"SECONDARY","title":"First-dose AUC0-t of Retifanlimab","description":"AUC0-t was defined as the area under the plasma or serum concentration-time curve from time = 0 to the last measurable concentration at time = t of retifanlimab.","populationDescription":"PK Evaluable Population","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"day*mg/L","timeFrame":"preinfusion and 10 minutes postinfusion (± 10 minutes) on Day 1 of Cycle 1","groups":[{"id":"OG000","title":"All Participants","description":"Participants with melanoma, non-small cell lung cancer, urethelial carcinoma, and renal cell carcinoma received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"121"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1620","spread":"506"}]}]}]},{"type":"SECONDARY","title":"AUC0-t of Retifanlimab at Steady-state","description":"AUC0-t was defined as the area under the plasma or serum concentration-time curve from time = 0 to the last measurable concentration at time = t of retifanlimab.","populationDescription":"PK Evaluable Population","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"day*mg/L","timeFrame":"preinfusion and 10 minutes postinfusion (± 10 minutes) on Day 1 of Cycles 1, 2, 4, and 6 (up to approximately 168 days; each cycle was 28 days)","groups":[{"id":"OG000","title":"All Participants","description":"Participants with melanoma, non-small cell lung cancer, urethelial carcinoma, and renal cell carcinoma received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"121"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2030","spread":"566"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Adverse events were assessed for up to approximately 2.3 years. All-Cause Mortality was assessed for up to 28.2 months","description":"Treatment-emergent adverse events, defined as any adverse events either reported for the first time or the worsening of pre-existing events after the first dose of retifanlimab and until the earlier of 90 days of the last administration of retifanlimab and new anti-cancer therapy start if any, are reported.","eventGroups":[{"id":"EG000","title":"Melanoma","description":"Participants with melanoma received retifanlimab 500 milligrams (mg), administered by intravenous (IV) infusion over 30 minutes on Day 1 of each 28-day cycle (Q4W).","deathsNumAffected":16,"deathsNumAtRisk":35,"seriousNumAffected":8,"seriousNumAtRisk":35,"otherNumAffected":30,"otherNumAtRisk":35},{"id":"EG001","title":"Non-small Cell Lung Cancer","description":"Participants with non-small cell lung cancer received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W.","deathsNumAffected":11,"deathsNumAtRisk":23,"seriousNumAffected":9,"seriousNumAtRisk":23,"otherNumAffected":19,"otherNumAtRisk":23},{"id":"EG002","title":"Urothelial Cancer","description":"Participants with urethelial carcinoma received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W.","deathsNumAffected":17,"deathsNumAtRisk":29,"seriousNumAffected":12,"seriousNumAtRisk":29,"otherNumAffected":25,"otherNumAtRisk":29},{"id":"EG003","title":"Renal Cell Carcinoma","description":"Participants with renal cell carcinoma received retifanlimab 500 mg, administered by IV infusion over 30 minutes on Day 1 Q4W.","deathsNumAffected":10,"deathsNumAtRisk":34,"seriousNumAffected":11,"seriousNumAtRisk":34,"otherNumAffected":30,"otherNumAtRisk":34},{"id":"EG004","title":"Total","description":"Total","deathsNumAffected":54,"deathsNumAtRisk":121,"seriousNumAffected":40,"seriousNumAtRisk":121,"otherNumAffected":104,"otherNumAtRisk":121}],"seriousEvents":[{"term":"Abdominal pain lower","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Arterial occlusive disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Bone lesion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Bronchial obstruction","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"COVID-19 pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":121}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":121}]},{"term":"Cognitive disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Extrapyramidal disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Haemorrhage","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Hepatocellular injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":121}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Hypertensive crisis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Hyperthermia","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Hypophysitis","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Malignant melanoma in situ","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Myelodysplastic syndrome","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Orchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Paroxysmal atrioventricular block","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":34},{"groupId":"EG004","numEvents":6,"numAffected":6,"numAtRisk":121}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":121}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Rectal adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Right ventricular failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":121}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Systemic inflammatory response syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Tumour associated fever","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":121}]},{"term":"Vena cava thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":121}]}],"otherEvents":[{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":6,"numAffected":5,"numAtRisk":121}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":6,"numAffected":6,"numAtRisk":121}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG004","numEvents":8,"numAffected":7,"numAtRisk":121}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":121}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":9,"numAffected":9,"numAtRisk":29},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":34},{"groupId":"EG004","numEvents":17,"numAffected":17,"numAtRisk":121}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":35},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":6,"numAffected":5,"numAtRisk":121}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":15,"numAffected":8,"numAtRisk":29},{"groupId":"EG003","numEvents":13,"numAffected":5,"numAtRisk":34},{"groupId":"EG004","numEvents":38,"numAffected":21,"numAtRisk":121}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":7,"numAtRisk":35},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG002","numEvents":11,"numAffected":9,"numAtRisk":29},{"groupId":"EG003","numEvents":7,"numAffected":6,"numAtRisk":34},{"groupId":"EG004","numEvents":31,"numAffected":24,"numAtRisk":121}]},{"term":"Azotaemia","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":121}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":29},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":34},{"groupId":"EG004","numEvents":11,"numAffected":10,"numAtRisk":121}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":121}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":29},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":34},{"groupId":"EG004","numEvents":10,"numAffected":9,"numAtRisk":121}]},{"term":"Blood thyroid stimulating hormone increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":121}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":121}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":121}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":4,"numAffected":3,"numAtRisk":121}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG002","numEvents":9,"numAffected":6,"numAtRisk":29},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":34},{"groupId":"EG004","numEvents":17,"numAffected":14,"numAtRisk":121}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":4,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":34},{"groupId":"EG004","numEvents":13,"numAffected":9,"numAtRisk":121}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":35},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":23},{"groupId":"EG002","numEvents":8,"numAffected":7,"numAtRisk":29},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":34},{"groupId":"EG004","numEvents":20,"numAffected":19,"numAtRisk":121}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":7,"numAtRisk":35},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":23},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":29},{"groupId":"EG003","numEvents":7,"numAffected":4,"numAtRisk":34},{"groupId":"EG004","numEvents":38,"numAffected":19,"numAtRisk":121}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":34},{"groupId":"EG004","numEvents":5,"numAffected":5,"numAtRisk":121}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":5,"numAffected":4,"numAtRisk":34},{"groupId":"EG004","numEvents":12,"numAffected":10,"numAtRisk":121}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":35},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":6,"numAffected":6,"numAtRisk":34},{"groupId":"EG004","numEvents":14,"numAffected":12,"numAtRisk":121}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":121}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":5,"numAffected":5,"numAtRisk":121}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":4,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":8,"numAffected":5,"numAtRisk":121}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":35},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG004","numEvents":13,"numAffected":12,"numAtRisk":121}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":121}]},{"term":"Groin pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":121}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":121}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":121}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":35},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":10,"numAffected":9,"numAtRisk":121}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":121}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG004","numEvents":6,"numAffected":5,"numAtRisk":121}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG004","numEvents":8,"numAffected":6,"numAtRisk":121}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":121}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG004","numEvents":6,"numAffected":6,"numAtRisk":121}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":34},{"groupId":"EG004","numEvents":11,"numAffected":11,"numAtRisk":121}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":34},{"groupId":"EG004","numEvents":5,"numAffected":5,"numAtRisk":121}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":34},{"groupId":"EG004","numEvents":4,"numAffected":3,"numAtRisk":121}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":121}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":121}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":6,"numAffected":6,"numAtRisk":121}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":121}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":29},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":34},{"groupId":"EG004","numEvents":12,"numAffected":12,"numAtRisk":121}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":4,"numAffected":3,"numAtRisk":121}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":29},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":34},{"groupId":"EG004","numEvents":11,"numAffected":10,"numAtRisk":121}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":121}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":5,"numAffected":3,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG004","numEvents":10,"numAffected":8,"numAtRisk":121}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":34},{"groupId":"EG004","numEvents":8,"numAffected":8,"numAtRisk":121}]},{"term":"Pelvic pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":121}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":6,"numAffected":4,"numAtRisk":34},{"groupId":"EG004","numEvents":9,"numAffected":7,"numAtRisk":121}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":9,"numAtRisk":35},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":23},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":29},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":34},{"groupId":"EG004","numEvents":25,"numAffected":21,"numAtRisk":121}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":3,"numAtRisk":35},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG002","numEvents":7,"numAffected":4,"numAtRisk":29},{"groupId":"EG003","numEvents":8,"numAffected":4,"numAtRisk":34},{"groupId":"EG004","numEvents":23,"numAffected":13,"numAtRisk":121}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":5,"numAtRisk":35},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":29},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":34},{"groupId":"EG004","numEvents":22,"numAffected":15,"numAtRisk":121}]},{"term":"Rash macular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":121}]},{"term":"Rash pustular","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":121}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":121}]},{"term":"Sciatica","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":4,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":5,"numAffected":3,"numAtRisk":121}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":34},{"groupId":"EG004","numEvents":3,"numAffected":2,"numAtRisk":121}]},{"term":"Skin toxicity","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":121}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":121}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":121}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":35},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":23},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":29},{"groupId":"EG003","numEvents":6,"numAffected":5,"numAtRisk":34},{"groupId":"EG004","numEvents":21,"numAffected":17,"numAtRisk":121}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":121}]},{"term":"Vitiligo","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":121}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":35},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG002","numEvents":4,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG004","numEvents":9,"numAffected":6,"numAtRisk":121}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":121}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results."},"pointOfContact":{"title":"Study Director","organization":"Incyte Corporation","email":"medinfo@incyte.com","phone":"1-855-463-3463"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2021-06-23","uploadDate":"2022-04-13T09:16","filename":"Prot_000.pdf","size":886220},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2021-06-23","uploadDate":"2022-04-13T09:16","filename":"SAP_001.pdf","size":572939}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D008545","term":"Melanoma"},{"id":"C538445","term":"Clear-cell metastatic renal cell carcinoma"},{"id":"D002292","term":"Carcinoma, Renal Cell"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D018358","term":"Neuroendocrine Tumors"},{"id":"D017599","term":"Neuroectodermal Tumors"},{"id":"D009373","term":"Neoplasms, Germ Cell and Embryonal"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009380","term":"Neoplasms, Nerve Tissue"},{"id":"D018326","term":"Nevi and Melanomas"},{"id":"D012878","term":"Skin Neoplasms"},{"id":"D012871","term":"Skin Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"},{"id":"D000230","term":"Adenocarcinoma"},{"id":"D002277","term":"Carcinoma"},{"id":"D009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D007680","term":"Kidney Neoplasms"},{"id":"D014571","term":"Urologic Neoplasms"},{"id":"D014565","term":"Urogenital Neoplasms"},{"id":"D052776","term":"Female Urogenital Diseases"},{"id":"D005261","term":"Female Urogenital Diseases and Pregnancy Complications"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D007674","term":"Kidney Diseases"},{"id":"D014570","term":"Urologic Diseases"},{"id":"D052801","term":"Male Urogenital Diseases"}]}},"hasResults":true}